GHP Q3 2021

26 GHP / Q3 2021 GHP / Q3 2021 27 , , Jun21249 Having earned the award for the ‘Most Outstanding Aesthetic & Skin Care Specialist of the Year’ in 2021, Noon Aesthetics UK – distributed by Advanced Esthetics Soltutions Ltd – has beenmaking a name for itself. Being relatively new to the market, it wasted no time in becoming a household name amongst beauticians and cosmetic experts, supplying them with its top-of-the-range and diligently researched products. Noon Aesthetics UK is the product line of stunning, outstanding, professional cosmeceutical and prescriptive skincare distributed by Advanced Esthetics Solutions. These products already serve a wide market segment, distributed across 30 different countries, providing worldwide and advanced aesthetic products since late 2019, bringing these innovative technologies and impressive results to the UK’s marketplace. Each product is manufactured in Israel Noon under an ancient philosophy – one of tapping into ‘primordial waters’ – that are believed to have the power to embody all that is good in the world. It, therefore, seeks to mirror these waters with everything it creates, believing that excellence, professionalism, and quality is what inherently leads to success as it naturalistically builds up its business over time by earning the support and trust of its customers. Moreover, each product has been created by a trusted Noon Aesthetics clinician, not available for online purchase or wholesale. In this way, it keeps the experience of purchasing its products a person-to-person affair, able to keep a close eye A New Line of Products for the UK’s Cosmetic Professionals Havingmade itself the ‘Best Pharmaceutical Equipment Sales and Service Company’ in 2021 for the United Kingdom, Biopharma Group is a business operating across the world to support and bolster the production and development of projects for the pharmaceutical, biotech and associated industries. Inmaking itself the backbone to its clients’ operations with tailored, in-depth, customer focused work, its efforts over the past year have been invaluable in facing the challenges of the pandemic. Providing its clients with high standard support, products, and services in the biotechnology and pharma industries, Biopharma Group has held to a mission of meeting the precise needs of its customers’ projects since day one. It will also ensure that its work is to-scale with the client’s project, always striving to provide the most appropriate solutions for the task at hand, and with the experience to do effectively. Fundamentally, this covers everything from the purchase of capital equipment through to R&D and manufacture consultancy services for customers creating the sector’s newest innovations, including pre- and post lyo cycle development, lyo training courses, contract manufacturing and more, augmenting the customer’s existing expertise in order to make for a collaborative success. In this way, Biopharma Group displays its customer-centric ethos from the very first time a client gets in touch, something that ensures its clientele that it will only ever advise what is best for their business and project by gaining an in-depth understanding of a customer’s requirements. Keeping the customer at its core, is what drives Biopharma Group forward. By collaborating with its clients thusly, it makes itself a partner to their business practices, taking on a proactive approach – one Expert Work, Professionally Augmented on the quality of what it creates in order to ensure that each step towards further growth is scalable with the high product value it strives to guarantee in every batch. Its products are also all vegan, and it has been able to develop a client list of skincare specialists, dermatologists, doctors, and experienced therapists who rely on it to stock them, setting itself apart with its gentle formulas that don’t cause painful flareups or reactions. With the addition of its patented DERMSHIELD product, its products contain active ingredients at breakthrough concentration levels with a PH under 1, allowing the product to penetrate down to the skin’s dermis layer, and inhibiting type C nociceptors. This allows for its homecare products to be used during pregnancy and makes its chemical peels available to all skin types. Noon Aesthetics products are, importantly, offered by its own clinical professionals, or by the professionals that it sells to. Its team are therefore pivotal to its business model, each of them being highly trained and talented with a deep love for its industry, investing in their wellbeing and personal professional development at every turn in order to thank them for their hard work. Noon Aesthetics believes in science; in all of its products, it champions the ideas of transparency, scientific rigour, and lack of fiction – therefore, it will always be honest about what ingredients are in a certain product, and its professionals will work with a client in order to find the product that is right for them. Essentially, this allows Noon Aesthetics to create real results for real people, building up an expansive portfolio and adding to the portfolio of Advanced Esthetics Solutions as a direct result, allowing both to grow in trust and notoriety within the UK market. Therefore, Noon Aesthetics is an important part of the brand name, and it makes the job of Advanced Esthetics Limited an easy one as distributors, as the products very much speak for themselves, having garnered significant goodwill amongst the UK’s aesthetic professionals. Company: Noon Aesthetics UK distributed by Advanced Esthetics Solutions Ltd Contact: Cody Gales Website: / / Jun21111 that has allowed the group to grow from a focus on freeze drying devices to multiple products – across its multiple divisions in the UK, Ireland, France, USA. Moreover, Biopharma Group’s widespread operation allows it to serve a myriad of diverse clients. This has influenced its ability to provide the highest levels of tailored support and services, as it has a vast portfolio of experience in its industry, working with a variety of specialists, and meeting the precise needs of the projects according to scale and size. Furthermore, to delve deeper into its work, its equipment sales and technical services teams have an in-depth knowledge of the equipment its supplies, especially when it comes to freeze dryers and associated processing technologies such as centrifugal solvent evaporators; meanwhile, its lyo lab and training division provides unbiased contract research, analysis, and development including industry specific lyo training and analytical instrumentation. Biopharma Technologies France (BTF) is able to offer a combined provision of equipment sales, lyo lab/CRO and lyo training, granting its French customers a dedicated single source solution. Additionally, although its focus still remains pharmaceuticals, biologics, and biotech, 2020 saw a necessary shift toward diagnostics and vaccine development, scale-up, and optimisation, stepping up to the plate to help the industry cope with the demand created by the Covid-19 pandemic. This is made possible by its exemplary team, vital to the success of the company as a whole by working towards a larger goal of benefitting the sector on a global scale; it was their work that allowed Biopharma Group to respond to 2020’s increased demand on freeze dried materials and contract work for vaccinations and diagnostics. This was done in conjunction with Biopharma Group’s partners to allow for large scale distribution. With so much learned over the past year, it now turns to the future. With an ever-expanding equipment ranges portfolio including the addition of positive and negative pressure isolators, DNA amplification cabinets, and production freeze dryers from Gellert at the same time as increasing its in-house lyo production capacity for larger scale CRO and CDMO work – Biopharma Group has expanded its offerings in line with the needs and expectations of customers and industry requirements as a whole. Biopharma Group, in addition, is striving to work with its peers to develop product formulations suitable for both liquid and freeze-dried applications, since the global production of vaccines relies on liquid, whilst the mid-to-long term applications will likely require freeze dried methods to reduce the need for cold chain in climate sensitive places. Company: Biopharma Group Contact: [email protected] Website: